# Results in a population of 278 patients affirm statistically significant mortality reductions.Benefits observed across severity groups and in subjects with serious comorbidities.

*biotech · news · 2026-02-24 · The Manila Times*

## Key points

- Paridiprubart's Phase 3 data showed a 27% relative reduction in 28-day mortality across 278 patients.
- Mortality reduction benefits with paridiprubart were observed in less severe ARDS and key comorbidity subgroups.
- Edesa Biotech has filed provisional patent applications for paridiprubart's use in sepsis, AKI, and pneumonia.
- Paridiprubart's safety profile remained favorable with low adverse event rates in over 400 treated patients.
- Edesa is evaluating strategic collaborations to accelerate late-stage development and commercialization of paridiprubart.

**Companies:** Edesa Biotech, Inc.
**Countries:** Canada, United States

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/02/24/tmt-newswire/globenewswire/edesa-biotech-reports-additional-positive-results-from-phase-3-paridiprubart-study/2284058)

---

Canonical: https://newsio.io/n/1762b816-a684-42b9-96e0-63b5295724da/results-in-a-population-of-278-patients-affirm-statistically-significant-mortali
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works